Mircera (methoxy polyethylene glycol epoetin beta)

This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.

Mircera is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD) in:

  • Adult patients on dialysis and adult patients not on dialysis

  • Pediatric patients 5 to 17 years of age on hemodialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA Limitations of Use Mircera is not indicated and is not recommended for use:

  • In the treatment of anemia due to cancer chemotherapy

  • As a substitute for RBC transfusions in patients who require immediate correction of anemia Mircera has not been shown to improve quality of life, fatigue, or patient well-being.


This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsStoriesRoche careersPrivacy StatementLegal Statement